GYRE
HealthcareGyre Therapeutics, Inc.
$7.92
+$1.11 (+16.30%)
Jan 5, 2026
Price History (1Y)
Analysis
Gyre Therapeutics, Inc. is a biotechnology company within the healthcare sector. It has a market capitalization of $762.96M and generated revenue of $107.27M in its most recent trailing twelve months (TTM). The company employs 579 individuals. From a financial perspective, Gyre Therapeutics demonstrates substantial profitability with gross, operating, and profit margins at 95.5%, 22.7%, and 6.2% respectively. Returns on equity and assets are also notable at 10.0% and 5.3%. The company's balance sheet reveals $60.05M in cash and only $1.17M in debt, indicating a healthy liquidity position. The company's valuation is characterized by a price-to-earnings ratio of 158.40 for the TTM period and a forward P/E of 17.22. Revenue growth has been significant at 19.9% year-over-year (YoY), while earnings growth reached 166.2% YoY.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Visit website →Key Statistics
- Market Cap
- $762.96M
- P/E Ratio
- 158.40
- 52-Week High
- $13.75
- 52-Week Low
- $6.11
- Avg Volume
- 77.31K
- Beta
- 7.08
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 579